Definium Therapeutics, Inc. (DFTX) Stock Price & Analysis

Definium Therapeutics, Inc. (DFTX) closed at USD 37.96 on Thursday, October 29, 2026, down 0.37% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 38.1; the Oct 29, 2026 session ranged USD 37.79–39.11 on volume of 1,402,252 shares. Market capitalization is $5.10B, with a 52-week range of USD 10.47–49.7 (NMS). Source: Nexqual, retrieved October 29, 2026 at 20:21 UTC.

Also available as compact Markdown for AI agents: nexqual.com/DFTX.md

Key facts (DFTX)

• Insider open-market sales, last ~7 months: 11 Form 4 filings, $5.6M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 5 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.74 on a 1–5 scale) (19 analysts), mean target USD 72.56 (range 55–91).
• Total return with dividends: 1Y +183.5% vs S&P 500 +14.4%; 5Y +0.4% vs S&P 500 +79.1%.
• Next earnings: 2026-11-05, EPS estimate USD -0.56, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DFTX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (DFTX)

P/B 5.5x · Earnings yield -6.94% · Net cash $1.05B · EV $4.05B

Insider sales (SEC Form 4, open-market, last ~7 months) (DFTX)

11 of 11 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (DFTX)

Consensus Buy (mean 1.74 on a 1–5 scale), 19 analysts; mean target USD 72.56 (low 55, high 91).

Rating changes, last 120 days:

Total return (dividends reinvested) (DFTX)

DFTX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

DFTX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

DFTX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

DFTX company outlook (results filed Aug 6, 2026)

• “Panorama results anticipated September 2026 Approximately $1.1 billion in cash, cash equivalents, and investments as of June 30, 2026 Conference call scheduled today at 4:30 p.m.”
• “Topline data anticipated the week of August 10, 2026. ▪ Completed enrollment of Phase 3 Panorama study (GAD) with 245 participants randomized 2:1:2 to receive DT120 ODT 100 µg, DT120 ODT 50 µg control, or placebo.”
• “Topline data anticipated in September 2026. ▪ Initiated enrollment of Phase 3 Ascend study (MDD).”
• “The trial is expected to enroll approximately 165 participants randomized 2:1:2 to receive DT120 ODT 100 µg, DT120 ODT 50 µg control, or placebo.”

Quoted word-for-word from the SEC 8-K results press release.

DFTX analyst estimates and revisions

DFTX options: expected move

Options price a move of about ±13.9% (±$5.33) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±4.6% on average.

30-day implied volatility 64.7% vs 53.2% realized over the last 30 trading days. Put/call ratio (volume) 0.15. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 20:21 UTC)

Technical Analysis (DFTX)

Nexqual's technical model rates DFTX "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 20:21 UTC.

Analyst Ratings (DFTX)

Wall Street analysts rate DFTX "Buy" based on 19 analysts, with a mean price target of USD 72.56 (range USD 55–91), per Nexqual as of October 29, 2026 at 20:21 UTC.

Earnings (DFTX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 20:21 UTC.

Financials & Fundamentals (DFTX)

Source: Nexqual, October 29, 2026 at 20:21 UTC.

Financial Health Score (DFTX)

Nexqual rates Definium Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 20:21 UTC.

Ownership (DFTX)

Source: Nexqual, October 29, 2026 at 20:21 UTC.

Leadership (DFTX)

Definium Therapeutics, Inc. is led by Robert Barrow, CEO & Director, per Nexqual as of October 29, 2026 at 20:21 UTC.

Major Backers & Investors (DFTX)

Notable institutional backers of Definium Therapeutics, Inc. include SmallCap World Fund Inc, Avoro Capital Advisors LLC, Driehaus Capital Management, LLC, according to Nexqual as of October 29, 2026 at 20:21 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 20:21 UTC.

From Definium Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our patent portfolio, as of February 19, 2026, contains 12 issued U.S. patents, 29 pending U.S. applications, and 1 pending patent cooperation treaty application that are either solely owned by us or in-licensed, as well as certain foreign counterparts of a subset of these patent applications in foreign countries, including Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Singapore, South Korea, and Taiwan.
• Our second lead product candidate, DT402 (previously referred to as MM402), also referred to as R(-)-MDMA, is our proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine ("MDMA"), which we are developing for the treatment of adults with autism spectrum disorder ("ASD").
• Lysergide tartrate, or DT120, is our proprietary product candidate, a pharmaceutically optimized form of lysergide D-tartrate being developed for GAD, MDD and other brain health disorders.
• R(-)-MDMA, or DT402, is our proprietary form of the R-enantiomer of MDMA, which we are developing for the treatment of ASD.

Partnerships

• In August 2023, we announced an exclusive licensing agreement with Catalent for its patented Zydis® ODT technology.
• On April 1, 2020, we entered into a multi-year, exclusive collaboration with Dr.

Legal & Regulatory Risks (Item 1A, quoted)

• We are subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation, fines and penalties; disruptions of our business operations, reputational harm, loss of revenue or profits, loss of customers or sales, and other adverse business consequences.
• Our business activities may be subject to the FCPA, CFPOA and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S., Canadian and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.
• We cannot guarantee that patent searches, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete and thorough, nor can we be certain that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction.
• We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time-consuming and unsuccessful.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:21 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt